Acelrx pharmaceuticals announces clinical data reporting high ratings for healthcare professional and patient satisfaction following use of dsuvia® for acute pain in hospital settings

Redwood city, calif., march 25, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of phase 3 data on the use of dsuvia for acute pain management in the postoperative and emergency department settings in the journal of pain research.
ACRX Ratings Summary
ACRX Quant Ranking